Circulating miR-16-5p, miR-92a-3p and miR-451a are biomarkers of lung cancer in Tunisian patients.
Biomarker
Diagnostic tools
Lung cancer
Prognostic
Tunisian population
miRNA
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
04 Apr 2024
04 Apr 2024
Historique:
received:
09
09
2023
accepted:
26
03
2024
medline:
5
4
2024
pubmed:
5
4
2024
entrez:
4
4
2024
Statut:
epublish
Résumé
Lung cancer is one of the most common type of cancer and, despite significant advances in screening and diagnosis approaches, a large proportion of patients at diagnosis still present advanced stages of the disease with distant metastasis and bad prognosis. Finding and validating biomarkers of lung cancer is therefore essential. Such studies are often conducted on European, American and Asian populations and the relevance of these biomarkers in other populations remains less clear. In that prospect, we investigated the expression level of seven microRNAs, chosen from the medical literature (miR-16-5p, miR-92a-3p, miR-103a-3p, miR-375-3p, miR-451a, miR-520-3p and miR-let-7e-5p), in the blood of Tunisian lung cancer patients, treated or not by chemotherapy, and healthy control individuals. We found that high expression levels of circulating miR-16-5p, miR-92a-3p and miR-451a in the plasma of untreated patients discriminate them from healthy control individuals. In addition, miR-16-5p and miR-451a expression levels are significantly reduced in the plasma of chemotherapy-treated patients compared to untreated patients. Our results confirmed previous work in other populations worldwide and provide further evidence that circulating miR-16-5p, miR-92a-3p and miR-451a potentially regulate key pathways involved in the initiation and progression of cancer.
Identifiants
pubmed: 38575987
doi: 10.1186/s12885-024-12181-1
pii: 10.1186/s12885-024-12181-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
417Subventions
Organisme : Labex "Who am I?"
ID : ANR-11-LABX-0071 and ANR-11-IDEX-005-02
Organisme : Labex "Who am I?"
ID : ANR-11-LABX-0071 and ANR-11-IDEX-005-02
Organisme : Fondation pour la Recherche Médicale
ID : AJE20151234749
Informations de copyright
© 2024. The Author(s).
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
doi: 10.3322/caac.21492
pubmed: 30207593
Zhou B, Zang R, Zhang M, Song P, Liu L, Bie F, et al. Worldwide burden and epidemiological trends of tracheal, bronchus, and lung cancer: a population-based study. EBioMedicine. 2022;78:103951.
doi: 10.1016/j.ebiom.2022.103951
pubmed: 35313216
pmcid: 8935504
Kemper M, Krekeler C, Menck K, Lenz G, Evers G, Schulze AB, et al. Liquid biopsies in lung cancer Cancers. 2023;15:1430.
pubmed: 36900221
Bianchi F, Nicassio F, Marzi M, Belloni E, Dall’olio V, Bernard L, et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med. 2011;3:495–503.
doi: 10.1002/emmm.201100154
pubmed: 21744498
pmcid: 3377091
Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A. 2011;108:3713–8.
doi: 10.1073/pnas.1100048108
pubmed: 21300873
pmcid: 3048155
Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol off J Am Soc Clin Oncol. 2014;32:768–73.
doi: 10.1200/JCO.2013.50.4357
Yu H, Guan Z, Cuk K, Brenner H, Zhang Y. Circulating microRNA biomarkers for lung cancer detection in western populations. Cancer Med. 2018;7:4849–62.
doi: 10.1002/cam4.1782
pubmed: 30259714
pmcid: 6198213
Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer. 2010;127:2870–8.
doi: 10.1002/ijc.25289
pubmed: 21351266
pmcid: 3545471
Yang X, Zhang Q, Zhang M, Su W, Wang Z, Li Y, et al. Serum microRNA signature is capable of early diagnosis for non-small cell lung cancer. Int J Biol Sci. 2019;15:1712–22.
doi: 10.7150/ijbs.33986
pubmed: 31360113
pmcid: 6643220
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.
doi: 10.1016/S0092-8674(04)00045-5
pubmed: 14744438
Jin X, Chen Y, Chen H, Fei S, Chen D, Cai X, et al. Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing. Clin Cancer Res off J Am Assoc Cancer Res. 2017;23:5311–9.
doi: 10.1158/1078-0432.CCR-17-0577
Leng Q, Lin Y, Jiang F, Lee C-J, Zhan M, Fang H, et al. A plasma miRNA signature for lung cancer early detection. Oncotarget. 2017;8:111902–11.
doi: 10.18632/oncotarget.22950
pubmed: 29340099
pmcid: 5762367
Reis PP, Drigo SA, Carvalho RF, Lopez Lapa RM, Felix TF, Patel D, et al. Circulating miR-16-5p, miR-92a-3p, and miR-451a in plasma from lung cancer patients: potential application in early detection and a regulatory role in tumorigenesis pathways. Cancers. 2020;12:2071.
doi: 10.3390/cancers12082071
pubmed: 32726984
pmcid: 7465670
Kumar S, Sharawat SK, Ali A, Gaur V, Malik PS, Kumar S, et al. Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients. Curr Probl Cancer. 2020;44:100540.
doi: 10.1016/j.currproblcancer.2020.100540
pubmed: 32007320
Montani F, Marzi MJ, Dezi F, Dama E, Carletti RM, Bonizzi G, et al. miR-Test: a blood test for lung cancer early detection. J Natl Cancer Inst. 2015;107:djv063.
doi: 10.1093/jnci/djv063
pubmed: 25794889
Xu X, Zhu S, Tao Z, Ye S. High circulating miR-18a, miR-20a, and miR-92a expression correlates with poor prognosis in patients with non-small cell lung cancer. Cancer Med. 2018;7:21–31.
doi: 10.1002/cam4.1238
pubmed: 29266846
Yu Y, Zuo J, Tan Q, Zar Thin K, Li P, Zhu M, et al. Plasma miR-92a-2 as a biomarker for small cell lung cancer. Cancer Biomark Sect Dis Markers. 2017;18:319–27.
doi: 10.3233/CBM-160254
Gan TQ, Chen WJ, Qin H, Huang SN, Yang LH, Fang YY, et al. Clinical value and prospective pathway signaling of MicroRNA-375 in lung adenocarcinoma: a study based on the Cancer Genome Atlas (TCGA), Gene expression Omnibus (GEO) and bioinformatics analysis. Med Sci Monit Int Med J Exp Clin Res. 2017;23:2453–64.
Patnaik S, Mallick R, Kannisto E, Sharma R, Bshara W, Yendamuri S, et al. MiR-205 and MiR-375 microRNA assays to distinguish squamous cell carcinoma from adenocarcinoma in lung cancer biopsies. J Thorac Oncol off Publ Int Assoc Study Lung Cancer. 2015;10:446–53.
Lu S, Kong H, Hou Y, Ge D, Huang W, Ou J, et al. Two plasma microRNA panels for diagnosis and subtype discrimination of lung cancer. Lung Cancer Amst Neth. 2018;123:44–51.
doi: 10.1016/j.lungcan.2018.06.027
Zhu W-Y, Luo B, An J-Y, He J-Y, Chen D-D, Xu L-Y, et al. Differential expression of miR-125a-5p and let-7e predicts the progression and prognosis of non-small cell lung cancer. Cancer Invest. 2014;32:394–401.
doi: 10.3109/07357907.2014.922569
pubmed: 24945821
Zhu H, Yang J, Yang S. MicroRNA-103a-3p potentiates chemoresistance to cisplatin in non-small cell lung carcinoma by targeting neurofibromatosis 1. Exp Ther Med. 2020;19:1797–805.
pubmed: 32104235
pmcid: 7027123
Lv X, Li CY, Han P, Xu XY. MicroRNA-520a-3p inhibits cell growth and metastasis of non-small cell lung cancer through PI3K/AKT/mTOR signaling pathway. Eur Rev Med Pharmacol Sci. 2018;22:2321–7.
pubmed: 29762835
Li X, Fu Q, Li H, Zhu L, Chen W, Ruan T, et al. MicroRNA-520c-3p functions as a novel tumor suppressor in lung adenocarcinoma. FEBS J. 2019;286:2737–52.
doi: 10.1111/febs.14835
pubmed: 30942957
Huang HY, Lin YCD, Cui S, Huang Y, Tang Y, Xu J, et al. miRTarBase update 2022: an informative resource for experimentally validated miRNA-target interactions. Nucleic Acids Res. 2022;50:D222–230.
doi: 10.1093/nar/gkab1079
pubmed: 34850920
Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 2019;47:W191–198.
doi: 10.1093/nar/gkz369
pubmed: 31066453
pmcid: 6602461
Huan T, Chen G, Liu C, Bhattacharya A, Rong J, Chen BH, et al. Age-associated microRNA expression in human peripheral blood is associated with all-cause mortality and age-related traits. Aging Cell. 2018;17:e12687.
doi: 10.1111/acel.12687
pubmed: 29044988
Sanaei M-J, Razi S, Pourbagheri-Sigaroodi A, Bashash D. The PI3K/Akt/mTOR pathway in lung cancer; oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles. Transl Oncol. 2022;18:101364.
doi: 10.1016/j.tranon.2022.101364
pubmed: 35168143
pmcid: 8850794
Elhamamsy AR, Metge BJ, Alsheikh HA, Shevde LA, Samant RS. Ribosome Biogenesis: a central player in cancer metastasis and therapeutic resistance. Cancer Res. 2022;82:2344–53.
doi: 10.1158/0008-5472.CAN-21-4087
pubmed: 35303060
pmcid: 9256764
Guo W, Du K, Luo S, Hu D. Recent advances of autophagy in non-small cell lung cancer: from basic mechanisms to clinical application. Front Oncol. 2022;12:861959.
doi: 10.3389/fonc.2022.861959
pubmed: 35600411
pmcid: 9115384
Wang Y, Zheng D, Tan Q, Wang MX, Gu L-Q. Nanopore-based detection of circulating microRNAs in lung cancer patients. Nat Nanotechnol. 2011;6:668–74.
doi: 10.1038/nnano.2011.147
pubmed: 21892163
pmcid: 3189330
Soussi G, Ben Alaya N, Chaouch N, Racil H. Development and validation of a prognostic index for survival in non-small cell lung cancer: results from a Tunisian cohort study. Cancer Epidemiol. 2018;53:111–8.
doi: 10.1016/j.canep.2018.01.018
pubmed: 29414630
Missaoui N, Hmissa S, Landolsi H, Korbi S, Joma W, Anjorin A, et al. Lung cancer in central Tunisia: epidemiology and clinicopathological features. Asian Pac J Cancer Prev APJCP. 2011;12:2305–9.
pubmed: 22296375
B’chir F, Pavanello S, Knani J, Boughattas S, Arnaud MJ, Saguem S. CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population. Life Sci. 2009;84:779–84.
doi: 10.1016/j.lfs.2009.03.008
pubmed: 19332078
B’chir F, Laouani A, Ksibi S, Arnaud MJ, Saguem S. Cigarette filter and the incidence of lung adenocarcinoma among Tunisian population. Lung Cancer Amst Neth. 2007;57:26–33.
doi: 10.1016/j.lungcan.2007.01.034